Find your next paid study

Aminex Therapeutics, Inc.NCT07287917

Phase 1

An Open-label, Multi-center, Phase I/Ib Study of IEV407 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therap…

Advanced HR+/HER2- Breast Cancer

Novartis PharmaceuticalsNCT07604571

Estrogen-receptor-positive Breast CancerHER2/Neu-Negative Breast CancerAdvanced Breast Cancerv+1 more

Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor

Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negat…

Northwestern UniversityNCT06062498

~$10 – $6,250

Phase 1

A Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients With Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug d…

Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more

Cogent Biosciences, Inc.NCT07361562

HER2-positive Breast Cancer

A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases

The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combinat…

Hoffmann-La RocheNCT07413939

Metastatic Breast CancerTriple Negative Breast CancerEstrogen-receptor-low Breast Cancer+1 more

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and n…

Kathy MillerNCT05846789

Breast CancerHER2-positive Breast CancerER Positive Breast Cancer+1 more

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Cancers Hoosier Cancer Research Network BRE17-141

Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, …

PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive Tumor+3 more

Ruth O'ReganNCT04886531

Phase 3

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib +…

Relay Therapeutics, Inc.NCT06982521

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal res…

Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in…

Breast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast Cancer+2 more

Dana-Farber Cancer InstituteNCT06488378

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

HER2-Positive Breast Carcinoma

Non-Small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation

~$10 – $750

Mayo ClinicNCT06557057

Phase 1

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor …